Clinical trial · Interventional
Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer
Clinical Phase II, Randomized, Double Blind Trial, to Evaluate the Efficacy of Metformin and Chemotherapy Versus Placebo Nad Chemotherapy in Neoadjuvant Setting for Locally Advanced Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background Obesity and overweight are well known risk factors for breast cancer and also are associated with higher recurrence and mortality rates. Main goal of this study is to evaluate the efficacy of metformin plus chemotherapy in terms of pathologic complete response in comparison with placebo plus the same chemotherapy regimen Design: Randomized, double blind, clinical trial. This study will be performed at National Cancer Institute of Mexico City, at breast cancer unit. Patients with ER+ or PR+, HER2 negative, breast cancer are candidates to participate. After completion of chemotherapy all patients will have a breast surgery to assess pathologic response. Complete pathologic response is defined as the abscence of malignant cells in breast tissue and lymph nodes. The presence of DCIS is considered as pCR
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Malignant Neoplasm | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metformin
- description
- Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
- interventionNames
- Drug: Metformin
Primary outcomes (1)
- measure
- pathologic complete response
- timeFrame
- pCR will be assesed after 24 weeks of treatment
- description
- to assess the efficacy in terms of pahtologic complete response in patients with locally advanced breast cancer, treated with neoadjuvant chemotherapy based on Paclitaxel followed by FAC, combined with metformin or placebo
Secondary outcomes (3)
- measure
- Safety analysis
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Women older than 18 years old and younger than 70 years old * Invasive breast cancer confirmed by core biopsy, any histology * Tumor ≥2 cm and/or lymph node positive (proven by FNA)(T2-4b, N0-3, M0) * Must have ER/PR positive and HER2 negative * Must have full staging and extent disease and clinically and radiographically tumor measure * Without previous treatment for breast cancer (including surgery, hormonotherapy or chemotherapy) * Normal liver, kidney and blood tests * Performance Status ECOG 0-2 o Karnofsky ≥70% * Fasten glucose levels \<125 mg/dl * Signed consent Exclusion Criteria: * Previous use of metformin for any indication * Presence of Diabetes Mellitus
References
Publications (0)
Data not yet available